general
- Generic Name : Ustekinumab
- Pronunciation : US-te-KIN-ue-mab
- ICD Code : Y43.4
- Therapeutic Classification : Monoclonal Antibodies
- Trade Names/Brand Names of Ustekinumab(International) : Stelara
prescription
Ustekinumab, a monoclonal antibody, is prescribed for psoriasis. It inhibits specific cells’ activity in the body, alleviating psoriasis symptoms.
risk factors
Hypersensitivity
side effects
Side effects may include cold symptoms, upper respiratory tract infection, headache, fatigue, diarrhea, back pain, dizziness, throat pain, itching, injection site redness, muscle pain, and depression.
dosage
For patients weighing less than 100kg:
- Initial dose: 45 mg
- Second dose (4 weeks later): 45 mg
- Maintenance dose: 45 mg every 12 weeks.
For patients weighing more than 100kg:
- Initial dose: 90 mg
- Second dose (4 weeks later): 90 mg
- Maintenance dose: 90 mg every 12 weeks.
how to take
It is available as a solution for injection, administered by a healthcare provider under the skin.
warning
- Use caution in patients with a history of infection, tuberculosis (TB), cancer, reversible posterior leukoencephalopathy syndrome (RPLS), immunodeficiency, flu-like symptoms, recent vaccination, allergies, concomitant medications, pregnancy, and breastfeeding.
- Perform a TB skin test before treatment initiation.
- Avoid contact with individuals with contagious infections.
- Refrain from live vaccinations during treatment.
- Patients may experience an increased risk of infections; consult a healthcare provider if necessary.
- There is a potential increased risk of malignancy.